"A lot of this had to do with the Allergan-Pfizer deal falling down and the Allergan CEO talking about other purchases they might make," Maley, an equity strategist at Miller Tabak, said Thursday on CNBC's "Power Lunch."

Analysts also have been looking at the effect the past five election cycles have had on biotech, according to Somaiya, an analyst at BMO.

"If you go back to the 2008 election cycle when health-care reform was such a hot topic and, obviously the follow-through was Obamacare, the group did underperform and it was probably the worst period for the Nasdaq biotech index," he said on "Power Lunch."